Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Propanc Biopharma Inc (PPCB) had Normalized Pre-Tax Income of $-18.86M for the most recently reported fiscal year, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-19.80M |
|
-- |
|
-- |
|
$18.19M |
|
$-18.19M |
|
$-0.68M |
|
$-18.86M |
|
|
Normalized Pre-Tax Income |
$-18.86M |
$-18.86M |
|
$-18.86M |
|
$-18.86M |
|
$-18.86M |
|
$-18.19M |
|
$-18.18M |
|
1.12M |
|
1.12M |
|
$-17.62 |
|
$-17.62 |
|
| Balance Sheet Financials | |
$8.54M |
|
$0.00M |
|
$4.24M |
|
$12.78M |
|
$3.35M |
|
-- |
|
$0.02M |
|
$3.38M |
|
$9.40M |
|
$9.40M |
|
$9.40M |
|
3.31M |
|
| Cash Flow Statement Financials | |
$-5.68M |
|
$-0.00M |
|
$6.46M |
|
$0.01M |
|
$0.83M |
|
$0.82M |
|
$0.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.55 |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.69M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-200.63% |
|
-200.63% |
|
-147.60% |
|
-200.63% |
|
$2.84 |
|
$-5.06 |
|
$-5.06 |
|